Immuneel Therapeutics is pleased to announce the appointment of Amit Mookim as Chief Executive Officer. With over 20 years of experience across life sciences, technology, and private equity, Amit is set to lead the next phase of growth and innovation for Immuneel in the cell and gene therapy space.
Amit joins Immuneel from IQVIA, where he served as Managing Director for South Asia, leading a team of over 20,000 professionals and driving significant commercial growth. Previously, he headed healthcare at KPMG India, where he helped establish and expand the firm’s healthcare practice, advising hospitals, private equity funds, and global healthcare companies.
A recognized thought leader, Amit has advised the National Health Authority on startup market access under the PMJAY scheme and worked with industry organizations like the Indian Pharmaceutical Alliance, APACMED, and FICCI. He has also contributed to leadership initiatives on universal healthcare, innovation, and regulatory collaborations across South Asia, APAC, the Middle East, and Europe.
Under his leadership, Immuneel will focus on expanding access to its CAR-T therapies, building global partnerships, and enhancing its presence in India and internationally. Co-founders Dr. Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee, and Dr. Kush Parmar are confident in Amit’s ability to guide the company’s mission of transforming cancer care.
The Immuneel team welcomes Amit as they continue to break new ground in cancer immunotherapy for patients in India and beyond.